Breaking News

Vetter to Introduce New V-OVS Syringe Closure System

New version will update the design, handling, and opening mechanism.

Vetter introduces the next evolution of the V-OVS syringe closure system.

Vetter, a global CDMO, will launch the new version of its V-OVS syringe closure system, V-OVS next, to support a range of sterile injectables integrating several unique technical advances guided by shifting market needs and feedback from customers. The design of V-OVS next will be optimized to protect the integrity of the injectable product secured by the closure. For customers with products in glass-barrel syringes, this new closure will be an opportunity to integrate Luer Lock features with easier handling characteristics and more intuitive opening mechanism.

“With its tamper-evident features, we’re confident that V-OVS next will bring a new level of user-friendliness to Luer Lock applications,” said Tobias Nemeth, Director Primary Packaging Service & Projects at Vetter. “It will further build on the decades of market impact delivered by this industry-leading system and provide a differentiating choice for customers with an even wider range of injectable products.”

Additionally, the overall size will also be reduced to better fit smaller syringe sizes. New updated gripping surfaces are designed to provide optimal control during opening, and a new locking mechanism will help keep the closure safely in place even during the most challenging clinical use cases.

V-OVS next is scheduled to launch in 2027. As part of its go-to-market preparations, Vetter recently conducted a successful human factors study with a representative group of frontline clinical users. The study delivered consistent positive feedback and insights that will directly contribute to finalizing the design of the new closure system.

Post-launch, Vetter will continue to offer both V-OVS and V-OVS next.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters